Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN increases full-year 2020 outlook
Venlo, the Netherlands, October 27, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2020 net sales growth to about 20% at constant exchange rates (CER) (prior outlook of 15-18% CER growth) and for adjusted earnings per share (EPS) to grow about 45% to approximately $2.07-2.09 CER (prior outlook for at least $2.00 CER per share) based on about 235 million shares outstanding.
The better-than-expected outlook reflects the strong performance in the first nine months of 2020 and expectations for an ongoing high level of sales and profitability in the fourth quarter of 2020. The outlook for the fourth quarter of 2020 is for about 24-27% CER growth in sales and for about $0.58-0.60 CER per share in adjusted EPS based on about 237 million shares outstanding.
QIAGEN has decided to bring forward the release of full results for the third quarter of 2020 to today, October 27, 2020.
QIAGEN plans to hold an investor conference call on Wednesday, October 28, 2020, at 14:00 Frankfurt time / 13:00 London time / 9:00 New York time. Further information about the results and the investor call are available in the Investor Relations section of
5912 PL Venlo
Frankfurt Stock Exchange, Regulated Market (Prime Standard)
Contacts QIAGEN N.V.:
John Gilardi, Tel: +49 2103 29 11711; firstname.lastname@example.org
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).